Indivior Pharmaceuticals, Inc. INDV Accrued Litigation
Accrued Litigation at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LitigationReserveNoncurrent.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's accrued litigation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's accrued litigation?
- Indivior Pharmaceuticals, Inc. (INDV) reported accrued litigation of $41M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's accrued litigation changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's accrued litigation decreased by 86.2% year-over-year, from $297M to $41M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's accrued litigation?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's accrued litigation has grown at a -61.9% compound annual growth rate (CAGR), from $359M to $52M.
- What does accrued litigation mean?
- This liability represents the estimated financial impact of ongoing legal proceedings, settlements, or regulatory investigations. It reflects management's best estimate of the costs required to resolve legal disputes that are considered probable and estimable. High or increasing balances in this category indicate significant legal risk and potential future cash outflows that could impact the company's financial stability.